Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02363504
Other study ID # NL51297.068.14
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2017
Est. completion date December 2020

Study information

Verified date February 2020
Source Maastricht University Medical Center
Contact Heidi Jacobs, PhD
Phone +31433884090
Email h.jacobs@maastrichtuniversity.nl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The cause of Alzheimer's disease, the most common form of dementia, remains unknown. Neuropathological studies suggest that a small area in the brainstem, the locus coeruleus, might be the site of the onset of the disease. This area is the sole source of noradrenalin to the brain, a neurotransmitter involved in arousal, but also cognitive functions. Animal and pharmacological studies have hinted towards an important role of this area in memory functioning. However, these studies were hampered by the limited spatial resolution, making it hard to clearly localize the locus coeruleus in the brain. New developments in brain imaging allow now to visualize the brain with stunning precision. Furthermore, a non-invasive new stimulation method, transcutaneous vagus nerve stimulation, is believed to excite the locus coeruleus and thereby influencing neuronal networks and memory functioning.

There are three aims in this project:

1. To investigate how the functional interaction between the locus coeruleus and other brain areas, in particular the medial temporal lobe areas, during memory processes (encoding, consolidation and retrieval) change with development of Alzheimer's disease.

2. To investigate associations between noradrenaline, memory performance and brain functioning. The investigators aim to investigate how acute noradrenalin levels change during the different memory processes and whether or not this is beneficial for performance. Furthermore, the investigators will investigate whether this interaction between noradrenalin, memory performance and brain functioning is different healthy older individuals (n =35) or patients with prodromal Alzheimer's disease (n =35).

3. To investigate the underlying neural network changes during transcutaneous vagus nerve stimulation. The investigators will focus on differences in functional connectivity between the locus coeruleus and the medial temporal lobe areas in healthy older individuals and prodromal Alzheimer's disease patients. An experimental condition will be compared with a sham condition in a pseudo-randomized cross-over design.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria:

For the patients:

- diagnosis of prodromal Alzheimer's disease based on the latest research criteria (clinical assessment at the memory clinic : presence of at least a memory impairment, memory complaints expressed by the patient or informant, no problems in daily life functioning, no dementia and presence of biomarkers

- Clinical Dementia Rating score of 0.5 (

- Mini-Mental State Examination (MMSE) = 23 and being mentally competent (in general, individuals with a MMSE = 18 are considered mentally competent)

- Age: between 60 and 85 years old

- 50% female

- Right-handedness

- Average level of education

- Informed consent before participation in the study

For the healthy older individuals:

- Average neuropsychological test results, in accordance with normative data, corrected for age, education and gender

- No substantial memory complaints (according to the participant)

- Age: between 60 and 85 years old

- 50% female

- Right-handedness

- Average level of education

- Informed consent before participation in the study

Exclusion Criteria:

- Reduced vision

- Psychoactive medication use

- Abuse of alcohol and drugs

- Cognitive impairment due to alcohol/drug abuse or abuse of other substances

- Past or present psychiatric or neurological disorders (major depression, schizophrenia, bipolar disorder, psychotic disorder (or treatment for it), epilepsy, stroke, Parkinson's disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Menière's disease, brain infections)

- Major vascular disorders (e.g. stroke)

- Heart diseases or pacemakers

- Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
7 Tesla MRI with memory task and non-invasive neurostimulation
This is not an intervention, we investigate the neural mechanisms

Locations

Country Name City State
Netherlands Maastricht University Maastricht

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Netherlands Organisation for Scientific Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Basic descriptives gender, date of birth, socio-economic status, educational level, medical history, medication use: will be used descriptively 15 minutes
Other Vascular measurements Mean arterial blood pressure, cardiovascular risk factors and vascular pathology will be assessed descriptively and could also lead to exclusion of participants. 15 min
Other Alpha-peak frequency the individual mean alpha-peak frequency will be assessed with rest EEG to determine stimulation parameters. 30 minutes
Other Side effects via a questionnaire we will collect the level of side effects after stimulation (scale 1-5) 10 min
Other Blood pressure and heart rate Blood pressure and heart rate will be measured before and after the sessions (seated and standing) in order to monitor response to the stimulation. 20 minutes
Primary Blood Oxygen Level Dependent (BOLD) response during a memory task BOLD response contrasts during encoding and retrieval. For encoding: comparing neutral versus emotional, comparing old versus prodromal AD and the interaction emotional level by group. For retrieval: correctly remembered versus those incorrectly remembered; neutral versus emotional faces; lures, mistakes and hits. These contrasts will be investigated comparing both groups.
BOLD responses during the memory task will also be compared across sessions (sham versus stimulation) for both groups.
Consolidation: task-free, so the BOLD response in the locus coeruleus will be correlated with the BOLD response in any other voxel of the grey matter of the brain over time (seed-based resting-state analyses).
60 minutes
Primary Performance on the memory task Mean reaction times and accuracy levels during encoding and retrieval for emotional and neutral face-name associations and for old and prodromal AD patients.
Mean reaction times and accuracy levels will also be compared across sessions: sham versus stimulation for both groups Mean reaction times and accuracy levels will also be correlated with BOLD responses during the memory task.
60 minutes
Primary Noradrenalin levels during the memory task Noradrenalin levels will be measured 7 times: double baseline, before encoding, after encoding, before retrieval, after retrieval and follow-up.
Noradrenalin levels will be correlated with BOLD responses during the memory task.
60 minutes
Secondary Grey matter volume of the locus coeruleus manual measurement of the number of voxels of the locus coeruleus: to compare groups 5 mintues
Secondary shape properties of the locus coeruleus Correspondence of the location between triangle meshes (shape of the locus coeruleus) will be compared between groups 5 minutes
Secondary Performance on neuropsychological tests Total score on the mini-mental state examination, fluency test, letter-digit-substitution test, concept shifting task, stroop color word test and the word learning task will be compared across groups. For the stroop color word task and the concept shifting task we will also compare reaction times between both groups.
These scores will be correlated to the grey matter volume of the locus coeruleus and the shape properties of the locus coeruleus.
30 minutes
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3